What Could Roche Holding (SWX:ROP) Reveal With New Phase III Cancer Data?

Roche Holding (SWX:ROP) and Genentech plan to present new Phase III lung and breast cancer data at the 2026 ESMO Annual Meeting. The late-stage divarasib results focus on lung cancer, providing fresh evidence on a next-generation targeted therapy approach. Giredestrant Phase III findings in breast cancer are set for a late-breaking session, highlighting updated outcomes in hormone-driven disease. The divarasib and giredestrant Phase III readouts only tell part of the story for Roche's...